Quick Search:

uzh logo
Browse by:

Zurich Open Repository and Archive 

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-57569

Beyer, C; Distler, O; Distler, J H W (2012). Biomarkers of fibrosis. In: Varga, J; Denton, C P; Wigley, F M. Scleroderma: From Pathogenesis to Comprehensive Management. Boston, 283-290. ISBN 978-1-4419-5773-3.

[img]Published Version
PDF - Registered users only


Biomarkers are modern diagnostics that can guide the treatment of our patients in daily clinical life and direct drug development in preclinical and clinical studies. Biological markers allow screening for diseases, giving prognostic information, and assessing disease activity. Over the last 20 years, biomarkers helped to prioritize drug development and minimize risks for drug attrition in late-phase clinical studies. Despite their central roles in modern medicine, the numbers of disease-specific biomarkers that we routinely assess in our patients with systemic sclerosis (SSc) are limited. So far, past medical history, clinical examination, and equipment-based diagnostics (e.g., computed tomography, body plethysmography, and right-heart catheterization studies) dominate our treatment decisions in SSc.

Item Type:Book Section, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Rheumatology Clinic and Institute of Physical Medicine
DDC:610 Medicine & health
Deposited On:09 Mar 2012 13:38
Last Modified:27 Nov 2013 16:29
Publisher DOI:10.1007/978-1-4419-5774-0_23
Related URLs:http://opac.nebis.ch/F/?local_base=NEBIS&CON_LNG=GER&func=find-b&find_code=SYS&request=007056852
Citations:Web of Science®. Times Cited: 1
Google Scholar™

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page